J&J paying $20M to settle Ohio opioid suits

The pharma giant joins Endo, Mallinckrodt and Allergan in reaching a settlement deal with Cuyahoga and Summit counties in Ohio.

By Ned Pagliarulo • Oct. 2, 2019

Look beyond ROI to optimize TV campaigns

Don’t leave precious dollars on the table.

By Crossix Solutions • Sept. 30, 2019

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

AstraZeneca, Merck strengthen lead in PARP drug class

AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.

By Jonathan Gardner • Sept. 28, 2019

Top Pelosi aide to payers: Help us defeat Big Pharma

Wendell Primus' pitch sparked debate between policy experts and industry representatives Monday at AHIP's annual conference.

By Samantha Liss • Sept. 24, 2019

Public health alert or legal advertising? It can be hard to tell.

"It's whack-a-mole; it really is," Aviva Wein, J&J's assistant general counsel for product liability, said of the increasing number of ads targeting devices.

By Dana Elfin • Sept. 24, 2019

Does disclosure of pharma payments harm patient trust in doctors?

A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.

By Andrew Dunn • Sept. 23, 2019

States pull back curtain on drug prices, to uncertain effect

A newly enacted law in Colorado requires pharma companies inform doctors of list prices, as well as the names of three generics in the same treatment class. 

By Ned Pagliarulo • Sept. 23, 2019

Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Regulatory barriers limit alternative state drug payment models

Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.

By Samantha Liss • Sept. 18, 2019

J&J finds competitive edge with latest Erleada approval

The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.

By Jacob Bell • Sept. 18, 2019

Vertex makes headway in UK reimbursement

Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.

By Jacob Bell • Sept. 12, 2019

Survey suggests Ionis is losing battle against Pfizer and Alnylam

Physician preferences between the company's respective drugs appear to be emerging in the year since Ionis' Tegsedi won approval. 

By Jacob Bell • Sept. 10, 2019

Pharma's reputation among Americans sinks to lowest level in decades: poll

According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

By Kristin Jensen • Sept. 4, 2019

Novartis secures NICE nod for Luxturna with discount offer

The U.K. cost agency recommended Luxturna after reaching a deal with Novartis, which sells the Spark gene therapy outside the U.S.

By Ned Pagliarulo • Sept. 4, 2019

Skyrizi looks ready to soar after strong launch

Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

By Jacob Bell • Sept. 4, 2019

Unblinded: Rebekah Gee's drug pricing experiment in Louisiana

Louisiana's health secretary negotiated a new payment model with Gilead for one of the poorest states in the country. Could it spread nationwide?

By Andrew Dunn • Aug. 28, 2019

Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds

Out-of-pocket spending on MS medications increased by more than 600% in the decade from 2006 to 2016, while the typical list price quadrupled.

By Andrew Dunn • Aug. 27, 2019

Pharmacogenetic test makers cheer UnitedHealth coverage. Other payers aren't there yet.

"I've been concerned that the hype around pharmacogenetics, at least for depression, has gotten out ahead of the data," said one psychiatry expert at Johns Hopkins.

By Graison Dangor • Aug. 27, 2019

Lilly's case for Taltz helped by expanded approval

By prescription numbers, Taltz trails Novartis' rival drug Cosentyx. An approval for use in ankylosing spondylitis will go some ways to level the playing field.

By Ned Pagliarulo • Aug. 26, 2019

Today's data linkage is tomorrow's privacy breach

Is your company at risk?

By Crossix Solutions • Aug. 22, 2019

Trump administration not giving up on plan to require prices in TV drug ads

Amgen, Merck and Eli Lilly successfully blocked the rule from taking effect in July, winning a district court decision that HHS is now appealing. 

By Ned Pagliarulo • Aug. 21, 2019

NHS coverage opens up Hemlibra to thousands more patients

The decision could help Roche's hemophilia drug make headway in the European market, especially among patients without inhibitors.

By Jacob Bell • Aug. 21, 2019

Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

Recently launched Mvasi and Kanjinti, copycat versions of Avastin and Herceptin respectively, will be preferred products for the insurer starting October 1. 

By Ned Pagliarulo • Updated Aug. 19, 2019

Nonprofit under pressure to make new TB drug affordable

Doctors Without Borders is calling on the TB Alliance to set a low price for the drug, and to put money from a sale of a regulatory fast pass toward patient access.

By Jacob Bell • Aug. 15, 2019

Gilead's Descovy set for PrEP approval, but not without data, access concerns

An expert panel recommended the FDA extend approval of Gilead's drug for preventive use, though advisers pushed for further study in cisgender women.

By Jacob Bell • Aug. 8, 2019